Treatments for influenza
Pro Research Analysisby 
Searched over 200M research papers
Treatments for Influenza: Current Options and Future Directions
Neuraminidase Inhibitors (NAIs) for Influenza Treatment
Neuraminidase inhibitors (NAIs) such as oseltamivir and zanamivir are the primary antiviral drugs used to treat influenza. These drugs work by inhibiting the neuraminidase enzyme, which is essential for the release of new viral particles from infected cells, thereby limiting the spread of the virus within the host 357. Early administration of NAIs, ideally within 48 hours of symptom onset, is crucial for maximizing their effectiveness in reducing the severity and duration of influenza symptoms 45.
Corticosteroids as Adjunctive Therapy
Corticosteroids are often prescribed for severe influenza due to their anti-inflammatory and immunomodulatory properties. However, their use remains controversial. Observational studies have shown that corticosteroid therapy is associated with increased mortality and a higher risk of hospital-acquired infections 19. The evidence is of very low quality, and there is a significant risk of confounding by indication, meaning that sicker patients are more likely to receive corticosteroids, which could skew the results 19. More high-quality research, including randomized controlled trials (RCTs), is needed to determine the true effectiveness and safety of corticosteroids in treating influenza 19.
Antiviral Combinations and Immunomodulatory Therapies
Combining antiviral drugs with different mechanisms of action is a promising strategy to enhance treatment efficacy and reduce the risk of resistance. For instance, combining NAIs with other antiviral agents or immunomodulatory drugs could potentially improve outcomes, especially in severe cases or in patients with novel influenza strains . Early-stage data suggest that such combinations may offer therapeutic benefits, but more clinical trials are needed to confirm these findings .
Emerging Antiviral Agents
New antiviral agents targeting different stages of the influenza virus life cycle are under development. Favipiravir, a polymerase inhibitor, and baloxavir marboxil, a cap-dependent endonuclease inhibitor, have shown promise in clinical trials and have been approved in some countries 36. These drugs offer a broader therapeutic window and a higher tolerance for resistance compared to traditional NAIs 36.
Host-Targeted Therapies
Influenza pathogenesis is influenced not only by viral replication but also by the host's inflammatory response. Therefore, therapies that modulate the host immune response are being explored. Anti-inflammatory drugs such as etanercept, statins, and cyclooxygenase-2 inhibitors may help reduce inflammation and protect lung epithelial cells from damage . Additionally, targeting therapies to the epithelium, such as using the neuraminidase mimic Fludase, can inhibit viral entry and minimize off-target effects .
Vaccination and Prophylaxis
Vaccination remains the most effective method for preventing influenza. Both inactivated and live attenuated vaccines are available, with the latter showing stronger mucosal and cell-mediated immune responses . However, the high mutation rate of the influenza virus necessitates the continuous development of new vaccines and antiviral drugs to keep up with emerging strains .
Conclusion
The treatment landscape for influenza includes a range of antiviral drugs, adjunctive therapies, and emerging treatments targeting both the virus and the host's immune response. While NAIs remain the cornerstone of antiviral therapy, new drugs like favipiravir and baloxavir marboxil offer promising alternatives. The use of corticosteroids is still debated, and more research is needed to clarify their role. Combination therapies and host-targeted treatments represent exciting areas of ongoing research, aiming to improve outcomes for patients with severe influenza.
Sources and full results
Most relevant research papers on this topic